Press Releases & Media Coverage
January 10, 2015
Dr. Cloud Paweletz's publication - "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA" - cited in Oncology Times "Best Lung Cancer Research of 2014".
January 7, 2015
Molecular Cancer Research (MCR) editorial group has selected a Belfer publication - “Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3” - to be reprinted in a 2014 Must-Read compilation for AACR.
April 21, 2014
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
April 7, 2014
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.
April 6, 2014
Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.
January 15, 2014
Findings from the Translational Research Lab within the Belfer Institute demonstrate that circulating DNA from non-invasive plasma samples is a promising biomarker to monitor response and predict resistance in the clinic.
November 29, 2013
Belfer scientists collaborate with W. Kaelin MD , to demonstrate that the Ikaros family of transcription factors are key downstream mediators of the efficacy of thalidomide-like drugs.
September 27, 2013
Pioneering study from the lab of Kwok Wong MD PhD, demonstrating that specific tumor mutations can drive immune escape, which has significant implications for the clinical development of immunomodulatory agents.
August 12, 2013
Pasi Janne, MD, PhD: Top 20 translational researchers in 2012